Download PDF
Exp Clin Endocrinol Diabetes 2016; 124(10): 593-596
DOI: 10.1055/s-0042-115639
Article
© Georg Thieme Verlag KG Stuttgart · New York

Evaluation of Ovarian Reserve with AMH Level in Patients with Well-Differentiated Thyroid Cancer Receiving Radioactive Iodine Ablation Treatment

F. Acıbucu
1   Department of Endocrinology, Sivas Numune Hospital, Sivas, Turkey
,
D. O. Acıbucu
2   Department of Biochemistry, Sivas Numune Hospital, Sivas, Turkey
,
Ö. B. Akkar
3   Department of Gynecology and Obstetrics, Cumhuriyet University Medical School, Sivas, Turkey
,
H. S. Dokmetas
4   Department of Endocrinology, Medipol University Medical School, Istanbul, Turkey
› Author Affiliations
Further Information

Publication History

received 30 April 2016
revised 28 July 2016

accepted 19 August 2016

Publication Date:
06 October 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: Radioactive iodine (RAI) ablation treatment is used for patients diagnosed with well-differentiated thyroid cancer in order to reduce the risk of recurrence. RAI ablation treatment can adversely affect gonads in males and females. In this study, we aimed to determine ovary damage and infertility risk due to RAI, using serum anti-Müllerian hormone (AMH) level, in females who received RAI ablation treatment.

Materials and Methods: 45 female patients who have not gone through the menopause and had received RAI ablation treatment for well-differentiated thyroid cancer in premenopausal period, and 40 healthy females as control groups were included in this study. The serum AMH, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), thyroid stimulating hormone (TSH) and creatinine levels of the patients included in the study were analyzed and compared to those of the control group with similar demographical characteristics.

Results: No differences were found between the patient group and control group in terms of age, height, weight, body mass index, LH, E2 and creatinine. The difference in AMH, FSH and TSH between both groups were found to be significant. There was no statistically significant relation between the age and AMH levels. Similarly, no statistically significant relation between RAI exposure duration and AMH levels was determined. When the patients below and above the age of 35 were compared with regard to AMH (2.95±1.79 and 2.75±1.94, respectively) and FSH (5.45±1.63 and 5.99±3.06, respectively), the difference between them was found to be statistically insignificant. Oligo/anovulation was detected in 7 patients (15.6% of the patient group) after RAI treatment, 8 (17.8%) patients became pregnant after RAI treatment, and none of the patients, who were actively trying to get pregnant, were unable to achieve it.

Conclusion: According to these results, it may be concluded that low AMH levels due to RAI treatment can cause damage to the ovaries of patients; nevertheless, considering the AMH levels and the absence of infertility in the patients, the infertility risk was found to be low.

Key words

anti-Müllerian hormone - radioactive iodine - thyroid cancer
 

  • References

  • 1 Wu JX, Young S, Ro K et al. Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer. Thyroid 2015; 25: 133-138
    CrossrefPubMedSearch in Google Scholar
  • 2 Cooper DS, Doherty GM, Haugen BR et al. American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214
    Search in Google Scholar
  • 3 Wichers M, Benz E, Palmedo H et al. Testicular function after radioiodine therapy for thyroid carcinoma. Eur J Nucl Med 2000; 27: 503-507
    CrossrefPubMedSearch in Google Scholar
  • 4 Hyer S, Vini L, O’Connell M et al. Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin Endocrinol (Oxf) 2002; 56: 755-758
    CrossrefPubMedSearch in Google Scholar
  • 5 Lushbaugh CC, Casarett GW. The effects of gonadal irradiation in clinical radiation therapy: a review. Cancer 1976; 37: 1111-1125
    CrossrefPubMedSearch in Google Scholar
  • 6 Sarkar SD, Beierwaltes WH, Gill SP et al. Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med 1976; 17: 460-464
    PubMedSearch in Google Scholar
  • 7 Durlinger AL, Gruijters MJ, Kramer P et al. Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 2002; 143: 1076-1084
    CrossrefPubMedSearch in Google Scholar
  • 8 Weenen C, Laven JS, Von Bergh AR et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004; 10: 77-83
    CrossrefPubMedSearch in Google Scholar
  • 9 La Marca A, Sighinolfi G, Radi D et al. Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16: 113-130
    CrossrefPubMedSearch in Google Scholar
  • 10 Iwase A, Nakamura T, Nakahara T et al. Assessment of ovarian reserve using anti-Müllerian hormone levels in benign gynecologic conditions and surgical interventions: a systematic narrative review. Reprod Biol Endocrin 2014; 12: 125
    CrossrefPubMedSearch in Google Scholar
  • 11 Peigné M, Decanter C. Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review. Reprod Biol Endocrin 2014; 12: 26
    CrossrefPubMedSearch in Google Scholar
  • 12 Decanter C, Morschhauser F, Pigny P et al. Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online 2010; 20: 280-285
    CrossrefPubMedSearch in Google Scholar
  • 13 Anderson RA, Cameron DA. Pretreatment serum anti-Müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 2011; 96: 1336-1343
    CrossrefPubMedSearch in Google Scholar
  • 14 Anderson RA, Rosendahl M, Kelsey TW et al. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer 2013; 49: 3404-3411
    CrossrefPubMedSearch in Google Scholar
  • 15 Anders C, Marcom PK, Peterson B et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 2008; 26: 286-295
    CrossrefPubMedSearch in Google Scholar
  • 16 Anderson RA, Themmen APN, Al-Qahtani A et al. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006; 21: 2583-2592
    CrossrefPubMedSearch in Google Scholar
  • 17 Yu B, Douglas N, Ferin MJ et al. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 2010; 116: 2099-2105
    CrossrefPubMedSearch in Google Scholar
  • 18 La Marca A, Stabile G, Artenisio AC et al. Serum anti-Müllerian hormone throughout the human menstrual cycle. Hum Reprod 2006; 21: 3103-3107
    CrossrefPubMedSearch in Google Scholar
  • 19 Haugen BR, Alexander EK, Bible KC et al. The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. American Thyroid Association Management guidelines for adult patients with Thyroid nodules and differentiated thyroid cancer: Thyroid 2016; 26: 1-133
    PubMedSearch in Google Scholar
  • 20 Sawka AM, Lakra DC, Lea J et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf) 2008; 69: 479-490
    CrossrefPubMedSearch in Google Scholar
  • 21 Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev 2010; 31: 702-755
    CrossrefPubMedSearch in Google Scholar
  • 22 Ceccarelli C, Bencivelli W, Morciano D et al. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab 2001; 86: 3512-3515
    CrossrefPubMedSearch in Google Scholar
  • 23 Hagen CP, Vestergaard S, Juul A et al. Low concentration of circulating antimüllerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study. Fertil Steril 2012; 98: 1602-1608
    CrossrefPubMedSearch in Google Scholar
  • 24 Steiner AZ, Herring AH, Kesner JS et al. Antimüllerian hormone as a predictor of natural fecundability in women aged 30–42 years. Obstet Gynecol 2011; 117: 798-804
    CrossrefPubMedSearch in Google Scholar
  • 25 La Marca A, Broekmans FJ, Volpe A et al. Anti-Müllerian hormone (AMH): what do we still need to know?. Hum Reprod 2009; 24: 2264-2275
    CrossrefPubMedSearch in Google Scholar
  • 26 Lee TH, Liu CH, Huang CC et al. Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reprod Biol Endocrin 2009; 7: 100
    CrossrefPubMedSearch in Google Scholar
  • 27 Behringer K, Mueller H, Goergen H et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin study group HD13 to HD15 trials. J Clin Oncol 2013; 31: 231-239
    CrossrefPubMedSearch in Google Scholar